Lipid metabolism disorders in patients with type 2 diabetes mellitus: focus on hypertriglyceridemia
https://doi.org/10.62751/2713-0177-2024-5-2-14
Abstract
The prevalence of diabetes mellitus (DM) is growing at an alarming rate worldwide. Diabetic complications are one of the leading causes of disability, morbidity and premature mortality. Along with chronic hyperglycemia, persistent systemic inflammation on the background of insulin resistance, dyslipidemia plays an important role in the development of macrovascular complications of diabetes. DM is characterized by the development of a mixed form of dyslipidemia, characterized by excessive accumulation of the most atherogenic forms of lipids. In most cases, hypertriglyceridemia occurs in type 2 diabetes. The most effective tool for correcting dyslipidemia today is fibrate therapy, including in combination with statins.
About the Authors
T. Yu. Demidova
Pirogov Russian National Research Medical University
Tatiana Yu. Demidova – D. Sci. (Med.), Prof.
1, Ostrovityanov St., Moscow, 117997
F. O. Ushanova
Pirogov Russian National Research Medical University
Fatima O. Ushanova – C . Sci. (Med.)
1, Ostrovityanov St., Moscow, 117997
References
1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium; 2021 Available from: https://www.diabetesatlas.org.
2. Дедов И. И., Шестакова М. В., Викулова О. К. и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–21. https://doi.org/10.14341/DM12759
3. Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care 1 November 2023 [Epub ahead of print]. DOI: 10.2337/dci23-0085
4. Nelson AJ, Navar AM, Mulder H, Wojdyla D, Philip S, Granowitz C, et al. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial). Am J Cardiol. 2020 Oct 1;132:36–43. DOI: 10.1016/j.amjcard.2020.07.005.
5. Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U. S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. Diabetes Care. 2019 Dec;42(12):2307–2314. DOI: 10.2337/dc19-0501.
6. Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia // Cardiovasc. Diabetol. 2015. Vol. 14. Article ID 115. https://doi.org/10.1186/s12933–015–0268–2
7. Robert H. Eckel. Arteriosclerosis, Thrombosis, and Vascular Biology. The Complex Metabolic Mechanisms Relating Obesity to Hypertriglyceridemia, Volume: 31, Issue: 9, Pages: 1946–1948, DOI: 10.1161/ATVBAHA.111.233049
8. Ghandehari H, Kamal-B ahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J. 2008 Jul;156(1):112–9. DOI: 10.1016/j.ahj.2008.03.005
9. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021 Dec 14;42(47):4791–4806. DOI: 10.1093/eurheartj/ehab551.
10. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(9):3939–3985
11. Luo Y., Peng D. Residual atherosclerotic cardiovascular disease risk: Focus on non-high-density lipoprotein cholesterol // J. Cardiovasc. Pharmacol. Ther. 2023. Vol. 28. Article ID 10742484231189597. https://doi.org/10.1177/10742484231189597
12. Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9–20. DOI: 10.2217/clp.10.84.
13. Ferreira JP, Vasques-Nóvoa F, Ferrão D, Saraiva F, Falcão-Pires I, Neves JS, et al. Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. Diabetes Care. 2022 Jul 7;45(7):1584–1591. DOI: 10.2337/dc211977.
14. Wang Y, Fang Y, Magliano DJ, Charchar FJ, Sobey CG, Drummond GR, Golledge J. Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes. Cardiovasc Res. 2023 May 2;119(3):826–834. https://doi.org/10.1093/cvr/cvac124
15. Гуревич В. С., Козиолова Н. А., Ежов М. В., Сергиенко И. В., Алиева А. С., Вавилова Т. В. и др. Нерешенные проблемы дислипидемии и резидуального сердечно-сосудистого риска // Атеросклероз и дислипидемии. 2022. Т. № 1 (46). СС. 31–39. DOI: https://doi.org/10.34687/2219-8202.JAD.2022.01.0003)
16. Nelson AJ, Navar AM, Mulder H, Wojdyla D, Philip S, Granowitz C, et al. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial). Am J Cardiol. 2020 Oct 1;132:36–43. DOI: 10.1016/j.amjcard.2020.07.005.
17. Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab 2018;20:1337–1341
18. Rodriguez-Gutierrez R, Garcia-Leal M, Raygoza-Cortez K, Flores-Rodríguez A, Moreno-Alvarado M, Heredia-M artínez EM, Vazquez-Baquerizo B, Guerra-Espiricueta R, Muñoz-Silva V, Gonzalez-Gonzalez JG. Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Endocrine. 2023 Aug;81(2):231–245. doi: 10.1007/s12020-023-03401-y.
19. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORD ION study. Cardiovasc Diabetol. 2020 Mar 5;19(1):28. DOI: 10.1186/s12933-020-01002-x.
20. Kyung An Kim, Na Jin Kim, Eun Ho Choo, The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis, European Journal of Preventive Cardiology, Volume 31, Issue 3, February 2024, Pages 291–301, https://doi.org/10.1093/eurjpc/zwad331.
21. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007 Nov 17;370(9600):1687–97. https://doi.org/10.1016/S0140–6736(07)61607–9
22. Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012 Nov 13;60(20):2061–71. doi: 10.1016/j.jacc.2012.07.049.
Review
For citations:
Demidova T.Yu., Ushanova F.O. Lipid metabolism disorders in patients with type 2 diabetes mellitus: focus on hypertriglyceridemia. FOCUS. Endocrinology. 2024;5(2):25-30. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-2-14
Views:
248
Email this article 